---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-115300"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:25:50.716289+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Iovance Q3 product revenue $58.6M; net loss narrows to $0.28/shr; FY24 guidance reaffirmed

## Summary
- Q3 2024 product revenue $58.6M ($42.1M Amtagvi, $16.5M Proleukin); net loss $83.5M ($0.28/shr) vs $113.8M ($0.46/shr) YoY.
- Reaffirms FY24 total product revenue guidance of $160-$165M and FY25 guidance of $450-$475M.
- 146 patients infused with Amtagvi since Apr 2024 launch; 82 infusions in Q3; 56 ATCs onboarded, targeting 70 by year-end.
- Regulatory submissions accepted in EU, UK, Canada; potential approvals in 1H2025 (UK) and 2H2025 (EU, Canada).
- Enrollment accelerating in IOV-LUN-202 Phase 2 NSCLC trial; potential accelerated U.S. approval for lifileucel in NSCLC expected in 2027.

## SEC filing metadata
- accession: 0001104659-24-115300
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465924115300/0001104659-24-115300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465924115300/tm2427769d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-115300
- JSON: https://secwatch.observer/filing/0001104659-24-115300.json
- Plain text: https://secwatch.observer/filing/0001104659-24-115300.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.